DNLI Q3'26 Earnings: EPS estimate is (0.32) USD

What happened

Denali Therapeutics is scheduled to report its Q3'26 results on November 03, after the market closes, with disclosure expected at 4:01 PM ET. The supplied estimate is revenue of 12.22 million USD and earnings per share, or EPS, of (0.32) USD.

Confirmed

Global impact / market context

The estimates set expectations for sales and loss per share, but they are not reported results. When the company releases actual figures, a difference from these estimates could change investors’ views of revenue progress and spending needs, influencing how they value Denali’s shares.

Analyst inference

Denali’s Q3’26 estimates show revenue of 12.22 million USD and earnings per share, or EPS, of (0.32) USD. The article says results are due after the market closes on November 03. These are estimates, not reported results, so actual revenue and loss per share could differ.

Analyst inference

What to watch

1. Check the November 03 release for actual revenue against the 12.22 million USD estimate; the gap would show whether sales exceeded or fell short of expectations. Confirmed
2. Compare reported EPS with the estimated (0.32) USD, and look for any company explanation of changes in costs or spending that could shape future losses. Confirmed
3. If revenue or EPS differs materially from estimates, investors may reassess Denali’s expected cash needs and share valuation, although the supplied article gives no guidance or cash figures. Analyst inference

Evidence

• Original source link unavailable